Neoadjuvant or adjuvant therapy for gastric cancer

Table 4 Adjuvant chemoradiotherapy in gastric carcinoma: Randomized trials

Studies	Country	Years	Randomization arms	Surgery	Protocol	Patients (n)	Overall survival	P value	Disease free survival	P value
INT 0116 trial[28,29]	United States	2001	Chemoradiotherapy and surgery	10% D2 surgery	5FU Mayo clinic/5FU RT	281	50% at 3 yr1	0.005	48% at 3 yr1	< 0.001
			Surgery alone			275	41% at 3 yr		31% at 3 yr
Chinese multicentre trial[33]	China	2012	Chemoradiotherapy and surgery	D2 surgery	5FU RT	186	48.4% at 5 yr	0.122	45.2% at 5 yr1	0.029
			Chemotherapy and surgery		5FU chemotherapy	165	41.8% at 5 yr		35.8% at 5 yr
ARTIST trial[31]	South Korea	2012	Chemoradiotherapy and surgery	D2 surgery	Xeloda CDDP/Xeloda RT	230	-	-	74.2% at 3 yr	0.086
			Chemotherapy and surgery		Xeloda CDDP	228	-		78.2% at 3 yr
CALGB 80101 trial[30]	United States	2011	Chemoradiotherapy and surgery	Not available	ECF/5FU RT	266	52% at 3 yr	0.8	47% at 3 yr	0.99
			Chemoradiotherapy and surgery		5FU Mayo/5FU RT	280	50% at 3 yr		46% at 3 yr

¹Statistically significant result. 5FU: 5-fluorouracil; RT: Radiotherapy; CDDP: Cisplatin.